COVID -19 hospital mortality and SARS-COV-2 vaccination influence: a retrospective analysis in a Mexican state cohort

Jesús Reyna Figueroa; Eduardo Castillo Robledo; Yolanda A Salyano Peñuelas; Francisco J Fernández Clamont

2024, Number 2

<< Back Next >>

Enf Infec Microbiol 2024; 44 (2)

COVID -19 hospital mortality and SARS-COV-2 vaccination influence: a retrospective analysis in a Mexican state cohort

Reyna FJ, Castillo RE, Salyano PYA, Fernández CFJ

Full text

How to cite this article

Language: Spanish
References: 27
Page: 47-52
PDF size: 242.87 Kb.

ABSTRACT

Introduction. The end of the COVID-19 health emergency has been declared, the role that vaccination played for its control must be disseminated to impact the population through policies, strengthening its importance in the prevention of complications, including death.
Material and methods. Through a case-control study, hospitalized subjects with a diagnosis of moderate to severe COVID-19 were included. The discharges due to death were considered cases and the controls were subjects who were discharged due to improvement of the acute condition. A bivariate analysis was used to determine the factors associated with death from COVID-19 and the odds ratio was calculated.
Results. A total of 29 250 (10.1%) subjects required hospitalization and 13 866 (47.4%) of them died. The highest percentage were unvaccinated patients with 62.1% and 6 655 (22.7%) had incomplete regimen. The percentage of vaccination coverage in the group of cases was 5.5%.
Conclusions. 74.4% of deaths from COVID-19 suffered from vaccination to this is added the 20% of those who presented incomplete scheme. It should not be forgotten however that control of other risk factors is necessary, as they have been continuously shown to influence an unwanted outcome.

REFERENCES

Zhang, J.J., Dong, X., Liu, G.H. y Gao, Y.D., “Risk and protectivefactors for covid-19 morbidity, severity, and mortality”,Clin Rev Allergy Immunol, 2023, 64 (1): 90-107.
Conahcyt, covid-19 en México (2023). Disponible en:https://datos.covid-19.conacyt.mx/.
Agrawal, U., Bedston, S., McCowan, C., Oke, J., Patterson,L., Robertson, C. et al., “Severe covid-19 outcomesafter full vaccination of primary schedule andinitial boosters: pooled analysis of national prospectivecohort studies of 30 million individuals in England, NorthernIreland, Scotland, and Wales”, Lancet, 2022, 400(10360): 1305-1320.
Nham, E., Song, J.Y., Noh, J.Y., Cheong, H.J. y Kim, W.J.,“covid-19 vaccination in Korea: past, present, and theway forward”, J Korean Med Sci, 2022, 37 (47): e351.
Organización Mundial de la Salud (oms), Orientacióntécnica sobre el nuevo coronavirus (2019-ncov). Disponibleen: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance. Consultadoel 19 de junio de 2023.
Krammer, F., “sars-cov-2 vaccines in development”, Nature,2020, 586: 516.
“Our world in data”. Disponible en: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL.
Statista Research Department, “Porcentaje de la poblaciónvacunada parcial y totalmente contra el coronavirusen México del 24 de diciembre de 2020 al 8 dejulio de 2022”. Disponible en: https://es.statista.com/estadisticas/1207749/porcentaje-vacunados-inmunizados-covid-19-mexico/.
Vacunas covid-19, Gobierno de México. Disponible en: https://coronavirus.gob.mx/2022/06/29/aplicadas-en-mexico-209-6-millones-de-vacunas-contra-covid-19/.
Gobierno del Estado de México, “Conoce el Edo Mex”.Disponible en: https://edomex.gob.mx/conoce_edomex.
Secretaría de Salud, “Aplicadas en México, 209.6 millonesde vacunas contra covid-19”. Disponible en: https://coronavirus.gob.mx/2022/06/29/aplicadas-en-mexico-209-6-millones-de-vacunas-contra-covid-19/.
SUIVE/dge/Secretaría de Salud/Estados Unidos Mexicanos2023.
INEGI, Censo de Población y Vivienda 2020. Disponible en:https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2021/EstSociodemo/ResultCenso2020_Nal.pdf.
Arce Salinas, C.A., Esquivel Torruco, Y.N., Bejarano Juvera,A.A., Bustamante Flores, A.K., Aguilar Martínez,N., Azcorra López, J.G., “Asociación entre la vacunacióncontra la influenza y la mortalidad por covid-19”, Vacunas,2022, 23 (2): 113-118.
Bouza, E., Ancochea, B.J., Campins, M., Eiros, B.J.M.,Fargas, J., García, R.A. et al., “The situation of vaccinesfor the prevention of infections in adults: an opinion paperon the situation in Spain”, Rev Esp Quimioter, 2019,32: 333-364.
Cascella, M., Rajnik, M., Aleem, A., Dulebohn, S.C. y DiNapoli, R., “Features, evaluation, and treatment of coronavirus(covid-19)”. En StatPearls, Treasure Island (FL),StatPearls Publishing, 2022.
Payne, J.R., Bose, S., Kubiak, R.W. y Nolen, L.D., “Evaluationof mortality risk after covid-19 vaccination, Utah2021”, Vaccine, 2023, S0264-410X (23):00380-388.
Tenforde, M.W., Self, W.H., Adams, K., Gaglani, M., Ginde,A.A., McNeal, T. et al., “Association between mrnavaccination and covid-19 hospitalization and diseaseseverity”, jama, 2021, 326 (20): 2043-2054.
Hippisley-Cox, J., Coupland, C.A., Mehta, N., Keogh,R.H., Díaz-Ordaz, K., Khunti, K. et al., “Risk prediction ofcovid-19 related death and hospital admission in adultsafter covid-19 vaccination: national prospective cohortstudy”, bmj, 2021, 374: n2244.
Stock, S.J., Carruthers, J., Calvert, C., Denny, C., Donaghy,J., Goulding, A. et al., “sars-cov-2 infection, andcovid-19 vaccination rates in pregnant women in Scotland”,Nat Med, 2022, 28 (3): 504-512.
Fendler, A., De Vries, E.G.E., Geurts van Kessel, C.H.,Haanen, J.B., Wörmann, B., Turajlic, S. et al., “covid-19vaccines in patients with cancer: immunogenicity, efficacy,and safety”, Nat Rev Clin Oncol, 2022, 19 (6): 385-401.
Al-Ali, D., Elshafeey, A., Mushannen, M., Kawas, H., Shafiq,A., Mhaimeed, N. et al., Cardiovascular and haematologicalevents post covid-19 vaccination: a systematicreview”, J Cell Mol Med, 2022, 26 (3): 636-653.
Chenchula, S., Karunakaran, P., Sharma, S. y Chavan, M.,“Current evidence on efficacy of covid-19 booster dosevaccination against the Omicron variant: a systematicreview”, J Med Virol, 2022, 94 (7): 2969-2976.
Fiolet, T., Kherabi, Y., MacDonald, C.J., Ghosn, J. y Peiffer-Smadja, N., “Comparing covid-19 vaccines for theircharacteristics, efficacy and effectiveness against sarscov-2 and variants of concern: a narrative review”, ClinMicrobiol Infect, 2022, 28 (2): 202-221.
Huang, Y.Z. y Kuan, C.C., “Vaccination to reduce severecovid-19 and mortality in covid-19 patients: a systematicreview and meta-analysis”, Eur Rev Med Pharmacol Sci,2022, 26 (5): 1770-1776.
Hippisley-Cox, J., Coupland, C.A., Mehta, N., Keogh,R.H., Díaz-Ordaz, K., Khunti, K. et al., “Risk prediction ofcovid-19 related death and hospital admission in adultsafter covid-19 vaccination: national prospective cohortstudy”, BMJ, 2021, 374: n2244.
Mohammed, I., Nauman, A., Paul, P., Ganesan, S., Chen,K.H., Jalil, S.M.S. et al., “The efficacy and effectivenessof the covid-19 vaccines in reducing infection, severity,hospitalization, and mortality: a systematic review”,Hum Vaccin Immunother, 2022, 18 (1): 2027160.